Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02203695 · ClinicalTrials.gov registry record · Phase 2
Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy
A Phase 2 study of Adenocarcinoma of the Prostate, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 2
- Development phase
- 86
- Enrollment target
- 9
- Study locations
NCT02203695: Completed Phase 2 study of Adenocarcinoma of the Prostate, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
NCT02203695 is a Phase 2 study of Adenocarcinoma of the Prostate that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 86 participants, below the 105-participant average among 21 other Adenocarcinoma of the Prostate trials with a reported enrollment target (18% lower). The trial reports 9 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02203695, a Phase 2 study of Adenocarcinoma of the Prostate, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 86 participants
- Enrollment target
- 9
- Study locations
Study Summary
The primary hypothesis of this study is that outcomes for patients with biochemically recurrent prostate cancer following radical prostatectomy will be improved by the addition of enzalutamide for 6-months compared to standard-of-care salvage radiation therapy to allow for further study in the definitive phase III setting. This study builds on the prior success of high-dose bicalutamide (for 24 months) when combined with salvage external radiation therapy (XRT), while using a newer more potent anti-androgen for a shorter duration of time (6 months) in an effort to minimize adverse effects.
Primary Outcome
The primary efficacy endpoint is the rate of Freedom-from-PSA-progression (FFPP) at 2-years. FFPP is defined as the time from randomization to the date of PSA progression. A subject who does not have PSA progression at the time of the analysis will be censored at the last date of PSA measurement.
Conditions Studied
Interventions
- DRUG Enzalutamide
- RADIATION SRT
Study Locations (9)
Maryland
- The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins - Baltimore
- Suburban Hospital - Bethesda
Michigan
- University of Michigan Health System - Ann Arbor
- Karmanos Cancer Center - Detroit
District of Columbia
- Sibley Memorial Hospital - Washington D.C.
Illinois
- University of Chicago Medical Center - Chicago
Indiana
- Indiana University - Lafayette
Oregon
- Oregon Health Sciences University - Portland
Utah
- University of Utah - Huntsman Cancer Center - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2015-03-28 |
| Est. Completion | 2022-12-31 |
| Phase | Phase 2 |
What the finished NCT02203695 record still lists
NCT02203695 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 86 participants, a relatively small participant target, below the 105-participant average among 21 other Adenocarcinoma of the Prostate trials with a reported enrollment target (18% lower).
The record links to 1 condition, with Adenocarcinoma of the Prostate appearing as the primary indexed condition, and to 2 interventions - of which Enzalutamide is the first listed.
NCT02203695 lists 9 locations in 7 states (Maryland, Michigan, District of Columbia).
Frequently Asked Questions
What is clinical trial NCT02203695 about?
NCT02203695 is a clinical study titled "Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy". The primary hypothesis of this study is that outcomes for patients with biochemically recurrent prostate cancer following radical prostatectomy will be improved by the addition of enzalutamide for 6-months compared to standard-of-care salvage radiation therapy to allow for further study in the defin...
What is the current status of trial NCT02203695?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 86 participants. The study started on 2015-03-28. Estimated completion is 2022-12-31.
What conditions does trial NCT02203695 study?
This clinical trial studies the following conditions: Adenocarcinoma of the Prostate.
What interventions are being tested in trial NCT02203695?
The interventions under investigation include: Enzalutamide (DRUG), SRT (RADIATION).
Who is sponsoring clinical trial NCT02203695?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02203695 being conducted?
This trial has 9 study locations across District of Columbia, Illinois, Indiana, Maryland, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adenocarcinoma of the Prostate
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02203695's enrollment target sits among peer trials
86 7th of 21 higher than 15 of 21 other Adenocarcinoma of the Prostate trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Adenocarcinoma of the Prostate trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dose-Escalated Proton Radiation Therapy for High-Risk Prostate Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Finasteride in Treating Patients With Stage II Prostate Cancer Who Are Undergoing Surgery
COMPLETED · Phase 2
-
A Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection
COMPLETED · Phase 2
-
Enzalutamide in Patients With High-risk Prostate Cancer
COMPLETED · Phase 2
-
Sorafenib Tosylate and Gene Expression Analysis in Patients Undergoing Surgery For High-Risk Localized Prostate Cancer
COMPLETED · Phase 2
-
17-AAG in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01639508 · 86 participants · Phase 2
Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
- NCT03519269 · 86 participants · NA
Navio Robotic Versus Conventional Total Knee Arthroplasty
- NCT04132999 · 86 participants · NA
PAP for Children With DS and OSAS
- NCT04545957 · 86 participants · NA
Jump: MR Simulation For Radiation Therapy Master Protocol
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI